Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral ...
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...
Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...
Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for ...
Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...
According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period ...